welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Mark J. Lucarelli, MD, FACS
University of Wisconsin School of Medicine
and Public Health
750 Highland Ave.
Madison, Wisconsin, United States
Mark J. Lucarelli is a Professor in the Department of Ophthalmology and Visual Sciences at University of Wisconsin, Madison, where he is Director of the Oculoplastics Service. His research interests center on surgical techniques and anatomic studies of the periocular structures. He has a special interest in thyroid eye disease (Graves’ orbitopathy) and serves on the International Thyroid Eye Disease Study Board (ITEDS).
Dr. Lucarelli received his medical degree from Washington University School of Medicine, St. Louis, Missouri followed by internship from Barnes-Jewish Hospital, St. Louis, Missouri; residency from Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; and fellowship in ophthalmic plastic and reconstructive surgery from University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Dr. Mark Lucarelli specializes in oculofacial surgery (also known as oculoplastic surgery or oculoplastics). Dr. Lucarelli is fellowship trained and is board certified by the American Board of Ophthalmology. He is a fellow of the American College of Surgeons and of the American Academy of Cosmetic Surgery. He serves as Program Director for an American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) sponsored fellowship in ophthalmic facial plastic surgery and is considered a national leader in his field.
Mark L. Malton, MDDr. Malton is certified by The American ...
Meeting of Dermatologic and Ophthalmic Drugs Advisory Committee AnnouncementThe committee will discuss biologics lic...
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
Timothy James McCulley, MDTimothy J. McCulley, MD, is the Vice-Cha...
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
Understanding Thyroid Eye DiseaseThyroid eye disease causes the muscles a...